Navigation Links
Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
Date:3/12/2013

SAN DIEGO, March 12, 2013 /PRNewswire/ -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.  LIPO-202, Lithera's lead product candidate, is a novel injectable pharmaceutical product designed to produce localized reduction of subcutaneous fat.

"Initiating the RESET trial is a significant milestone for Lithera and in the development of LIPO-202 as a non-ablative treatment for the aesthetic reduction of subcutaneous abdominal fat," stated George W. Mahaffey , President and CEO of Lithera.  "Following our recent Series C financing, Lithera is focused on advancing LIPO-202 in the clinic as we see tremendous potential for the drug to address a significant opportunity in aesthetic medicine – the ability to offer a quick and minimally invasive 'lunch time' procedure with no patient down time that effectively reduces abdominal fat."  

RESET is a 500-patient, multi-center, randomized, placebo-controlled clinical trial designed to measure the effects of three different doses of LIPO-202, compared to placebo, on abdominal bulging due to excess subcutaneous fat in healthy, non-obese subjects.  Patients randomized into each of the four trial arms will receive subcutaneous injections spaced evenly across the abdomen once per week for eight weeks.  Trial endpoints include multiple qualitative and quantitative measures of bulge reduction, as well as key safety information.

"The RESET trial incorporates indication-specific objective and subjective efficacy measures, as well as a suitably large sample size in order to provide what we hope to be a very clear demonstration of LIPO-202's effectiveness and a definition of its optimal dose," remarked Murray C. Maytom, MBChB, Chief Medical Officer of Lithera.  "Despite the trial's size, we expect top-line results in the third quarter of 2013 due to the short treatment duration and time to response, historically rapid trial enrollment, as well as strong interest from clinicians and patients in trial participation."

For more information on the Phase 2b trial of LIPO-202, including specific patient inclusion and exclusion criteria, please visit www.clinicaltrials.gov

About Lithera:

Lithera is a clinical stage company developing pharmaceutical and biomedical products addressing both lifestyle and medical indications in aesthetic medicine and ophthalmology. Using FDA-registered drugs approved for use in other indications, Lithera's products target and stimulate natural fat tissue metabolism to achieve non- ablative, non-surgical fat tissue reduction in specific locations. Our lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection), is a novel injectable pharmaceutical product designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty). LIPO-202 is currently under development for the aesthetic reduction of subcutaneous fat in the periumbilical area. LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate for Injection) is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (the thyroid condition is also known as Graves' Disease). Founded in 2007, the Company has assembled an exceptional team of senior executives, employees and advisors and has been financed by top-tier venture capital firms. For more information on Lithera, Inc., please visit www.lithera.com.

Lithera, LIPO-102, LIPO-202 and the Lithera logo are trademarks or registered trademarks of Lithera, Inc. Other names and brands may be claimed as the property of others.

 

Lithera, Inc.:  

Susan Knudson

Vice President, Finance & Administration

858-750-1008

sknudson@lithera.com

 

Media Inquiries:

Jason Rando / Andrew Mielach

Tiberend Strategic Advisors, Inc.

212-827-0020

jrando@tiberend.com

amielach@tiberend.com

 

 


'/>"/>
SOURCE Lithera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , January 23, 2017 A new Transparency ... Market was valued at US$0.53 bn in 2013 and is ... strong 17.50% CAGR between 2014 and 2022. The title of the ... Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the ... The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature ...
(Date:1/23/2017)... ... 2017 , ... "ProRandom is a set of camera tools that allow video editors to integrate ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, ... video footage. ProRandom works by using a virtual camera to create the illusion of ...
(Date:1/23/2017)... ... January 23, 2017 , ... “The Inn at the Mill”: a story of love and ... quest to become happy and content. , “The Inn at the Mill” is the ... in Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of ... Father. “Some Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. ... Baptist Church for thirteen years, a preacher for over nineteen, a pastor for over ...
(Date:1/22/2017)... ... 2017 , ... "Photo Cloud allows FCPX users to add favorited photos to ... ease," said Christina Austin - CEO of Pixel Film Studios. , To begin, ... timeline. Presets include scenes with one, three, four or five focus points. There are ...
Breaking Medicine News(10 mins):